Product Description
Humanized Anti-VEGF Monoclonal Antibody for Platinum-Resistant Recurrent Ovarian Cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03763123)
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Simcere
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Ovarian Cancer|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SIM-63-OC-101 | P1 |
Unknown status |
Ovarian Cancer |
2019-12-31 |
12% |
2024-11-27 |
Primary Endpoints|Treatments |
| SIM129-mCRC-01 | P1 |
Unknown status |
Colorectal Cancer |
2016-12-01 |
2024-11-27 |
Primary Endpoints |
|
| SIM-63-001 | P1 |
Unknown status |
Oncology Solid Tumor Unspecified |
2015-11-01 |
2019-03-19 |
Treatments |